HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, R. Articles by Mueller, D. L. Search for Related Content PubMed PubMed Citation Articles by Zhang, R. Articles by Mueller, D. L.

Casitas B-Lineage Lymphoma b Inhibits Antigen Recognition and Slows Cell Cycle Progression at Late Times during CD4⁺ T Cell Clonal Expansion¹

Department of Medicine and the Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Optimal clonal expansion of CD4⁺ T cells during the primary response to Ag requires prolonged TCR recognition of peptide Ag/MHC complexes. In this study, we investigated the capacity of Casitas B-lineage lymphoma b (Cbl-b) to counter-regulate late TCR signals necessary for continued cell division in vivo. During the first 24 h of a primary response to Ag, Cblb^–/– 5C.C7 CD4⁺ T cells demonstrated no alteration in CD69, CD25, and CD71 up-regulation or cell growth as compared with wild-type cells. Nevertheless, beyond 24 h, both the expression of CD71 and the rate of cell division were increased in the genetic absence of Cbl-b, leading to an augmented clonal expansion. This deregulation of late T cell proliferation in the absence of Cbl-b resulted in part from an inability of Cblb^–/– T cells to desensitize Akt, PLC-1, and ERK phosphorylation events downstream of the TCR/CD3 complex, in addition to their failure to undergo a growth arrest in the absence of Ag. These observations now suggest a novel role for Cbl-b in triggering the exit from cell cycle at the end of a CD4⁺ T cell clonal expansion.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Effective clonal expansion by naive CD4⁺ T cells that recognize Ag for the first time in the peripheral immune system relies on a prolonged period of Ag/MHC complex presentation and TCR ligation. Such persistent Ag recognition is facilitated in part by the activation of dendritic cells via their TLRs or CD40, leading to a decrease in the rate of Ag/MHC turnover (1, 2, 3). Experimental Ags designed for only transient dendritic cell expression confirm that CD4⁺ T cell clonal expansion and differentiation to effector or memory cell phenotypes is suboptimal when TCR ligation is terminated prematurely (4, 5). A failure of CD4⁺ T cells to continue to detect Ag/MHC complexes 24 h into a primary response promotes dissolution of T cell/dendritic cell tight interactions and reduces their proliferative potential (6). The use of an anti-Ag/MHC mAb to antagonize late TCR signaling has further revealed that CD4⁺ T cells immediately undergo a growth arrest and slow their rate of cell division once TCR ligands become unavailable (7). This counter-regulation of cell cycle progression in the absence of ongoing Ag/MHC recognition appears to underlie the clonal competition that limits clonal expansions by responder T cells already present at high frequencies (8, 9). However, there are as yet no data to support the notion that this regulation of late clonal expansion protects against the development of immunopathology.

In contrast, Casitas B-lineage lymphoma b (Cbl-b)³ has previously been implicated in the control of T cell-mediated immunopathology. Mutation of Cblb in the Komeda rat strain leads to spontaneous diabetes development (10). Mice made genetically deficient in Cbl-b expression also demonstrate infiltrations of multiple organs with activated T and B cells and the spontaneous production of anti-dsDNA autoantibodies, in addition to heightened sensitivity to the development of experimental autoimmune encephalomyelitis (11, 12). The biochemical mechanisms by which Cbl-b molecules regulate autoimmunity development are not entirely clear; however, emerging data suggest that TCR-triggered NFB-dependent gene expression is inhibited by Cbl-b in the absence of CD28 costimulatory signals (13). Consistent with this, Cbl-b limits the activation of protein kinase C- (PKC-) by Vav-1, thus controlling the formation of signaling rafts containing PKC-, CARMA1, and Bcl10 that regulate the IB kinase complex (11, 13). Cbl-b, a RING finger-containing E3 protein, has also been shown to bind to and catalyze the ubiquitination of the p85 regulatory subunit of PI3K, thereby inhibiting the activation of Akt in T cells (14, 15). Interestingly, the E3 ligase activity of Cbl-b is also thought to play an important role in the blockade of TCR signaling after T cell clonal anergy induction (16, 17, 18). Nevertheless, no previous experiments have investigated the role of Cbl-b in the regulation of late TCR signals.

This study now explores the capacity of Cbl-b to influence late events in CD4⁺ T cell clonal expansion in vivo. The results suggest that Cbl-b has little capacity to influence the entry of naive CD4⁺ T cells into cell cycle following immunization. However, the up-regulation of Cbl-b protein levels beyond 16–24 h of stimulation contributes to the premature growth arrest and slowing of the cell division rate that has been observed as Ag/MHC complex availability wanes. Therefore, these data support the hypothesis that Cbl-b opposes the development of immunopathology by facilitating CD4⁺ T cell exit from cell cycle.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Mice and Ag

Cblb^+/+ as well as Cblb^–/–Rag2^–/– 5C.C7 mice were provided by R. H. Schwartz (National Institutes of Health, Bethesda, MD) and were produced by back-crossing Cblb^+/– offspring (11) to Rag2^–/– 5C.C7 B10.A mice (19). Lymph node (LN) T cells from these 5C.C7 animals uniformly express Vβ3⁺ and CD4⁺, and recognize pigeon cytochrome c peptide 81–104 (PCCp)/I-E^k complexes. B10.A/Cr mice (B10.A) were purchased from Charles River Breeding Laboratories under a contract from the National Cancer Institute (Frederick, MD) and were used as syngeneic recipient mice for adoptive transfer studies. All mice were housed under specific pathogen-free conditions and used in accordance with guidelines put forth by the National Institutes of Health (Bethesda, MD) and the University of Minnesota Institutional Animal Care and Use Committee. Mice were sex and age matched for all experiments, ranging in age from 6 to 10 wk old.

T cell activation

For studies relying on the in vitro activation of CD4⁺ T cells, 5C.C7 LN cells (>95% pure) were first labeled with 5 µM CFSE (Molecular Probes), and then were incubated in complete medium (RPMI 1640 (Mediatech) containing 10% FCS (Atlas Biologicals), 2 mM L-glutamine, penicillin, streptomycin, and 5 x 10^–5 M 2-ME) for 16–24 h at 37°C on plates, in some cases precoated with anti-CD3 mAb (145-2C11) (20) and in the presence or absence of soluble anti-CD28 mAb (37.51) (21), or with hamster IgG (BD Biosciences) as an irrelevant Ab control, as previously described (22). Alternatively, T cells were stimulated with ionomycin and PMA (Calbiochem), or with human rIL-2 (Chiron), as indicated. In some experiments, 10 µg/ml Brefeldin A (Calbiochem) was added to cultures to inhibit the secretion of newly synthesized IL-2, and before its detection by intracellular staining and flow cytometry. In other experiments, IL-2 secretion was monitored in the supernatant using an ELISA system (BD Pharmingen). Finally, some cells were analyzed by Western blot using Santa Cruz Biotechnology Ab to Cbl-b and actin, as well as Cell Signaling Technology Ab to phospho-PLC, -Akt, -ERK, and -STAT5, as previously described (22).

Adoptive transfer

For in vivo adoptive transfer experiments, 2 x 10⁶ CFSE-labeled naive 5C.C7 CD4⁺ T cells were injected i.v. into B10.A mice. The next day, mice were immunized with PCCp alone at the indicated dosage (or PBS as a control) to initiate a CD4⁺ T cell clonal expansion at relatively high responder frequency and in the absence of an adjuvant. Alternatively, in vitro preactivated CFSE-labeled 5C.C7 CD4⁺ T cells were adoptively transferred into B10.A mice and then immediately challenged with PCCp.

Flow cytometry

Lymphocytes were harvested from either tissue culture plates or from the spleen and LNs of adoptive transfer recipient animals, and then immediately fixed with 2% formaldehyde (Sigma-Aldrich). Cells were then mixed with 2 x 10⁵ counting beads (Caltag Laboratories) and stained with an Ab mixture containing CD71- or CD69-PE, CD25-allophycocyanin, and CD4-PerCP-Cy5.5 (BD Pharmingen). Alternatively, cells were permeabilized with 0.5% saponin (Sigma-Aldrich) and stained with IL-2-PE and CD4- allophycocyanin (BD Pharmingen) as previously described (23). The majority of 5C.C7 CD4⁺ T cells were then distinguished from the endogenous polyclonal CD4⁺ T cell population based on a persistence of CFSE fluorescence in the FL1 channel and CD4 staining, using either a BD FACSCalibur or BD LSR II flow cytometer (BD Biosciences) and FlowJo analysis software (Tree Star).

Measurement of cell cycle progression in vivo

5C.C7 CD4⁺ T cell G₀G₁ cell cycle entry was monitored by flow cytometry using the forward scatter determination. The average cell division rate for the CFSE-labeled 5C.C7 CD4⁺ T cell population at various times after stimulation was calculated as previously described (7, 24). Briefly, based on the peaks of CFSE fluorescence intensity within the population, each T cell was assigned to a particular cell division group d (with d = 0 to n cell divisions), and the number of T cell events (E) observed within each cell division group (E_d) was determined. Average cell division (D) was then calculated using the following equation:

Note that this calculation of the average number of cell divisions is corrected for the 2-fold increase in cell number that is associated with each division. To allow for a comparison of D values between groups within an experiment, the SEM was determined for each sample using the following formula:

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Cbl-b counter-regulates the primary CD4⁺ T cell response to Ag stimulation in vivo

Mice made genetically deficient for Cbl-b have been shown to spontaneously produce autoantibodies and develop an immunopathology that is associated with multiorgan T and B cell infiltration (11, 12). Whether this immunopathology stems from a reduced threshold for the activation of the naive autoreactive lymphocytes in the absence of Cbl-b or from an inability of the clonal anergy tolerance mechanism to control the clonal expansion and effector function of Cblb^–/– self Ag-specific lymphocytes is uncertain. Furthermore, it remains unclear what effects a selection of autoreactive T cells and resulting immunopathology might have on the phenotype and function of CD4⁺ T cells taken from these mice.

To investigate the role of Cbl-b in the control of the CD4⁺ T cell primary response to Ag in the absence of confounding T cell autoreactivity or autoimmunity, we examined the proliferation of Rag2^–/– TCR-transgenic (Tg) 5C.C7 CD4⁺ T cells following their adoptive transfer into wild-type B10.A mice and stimulation with PCCp. Donor 5C.C7 mice lack the capacity to rearrange endogenous TCR gene loci and, therefore, avoid any self reactivity. For these experiments, we also took advantage of an immunization regimen capable of only suboptimal CD4⁺ T cell priming and known to induce a partial peripheral tolerance to Ag (23): PCCp was administered in the absence of adjuvant as a single i.v. bolus to wild-type recipient mice that had been adoptively transferred with 5C.C7 CD4⁺ T cells at a relatively high precursor frequency (2 x 10⁶). Exposure of the naive 5C.C7 CD4⁺ T cell population to 5 µg PCCp under these conditions elicited only a weak (4-fold) clonal expansion by 96 h that on average was associated with about two rounds of cell division (Fig. 1). Interestingly, Cbl-b acted in this system to moderate the response, as naive Rag2^–/– 5C.C7 CD4⁺ T cells made genetically deficient for Cblb demonstrated on average one additional round of cell division and accumulated to higher numbers following the immunization. Therefore, these data provided support for the hypothesis that Cbl-b acts within CD4⁺ T cells to counter-regulate Ag-induced proliferation in vivo even in the absence of systemic autoimmunity or lymphoproliferative disease.

View larger version (18K): [in this window] [in a new window]   FIGURE 1. Cbl-b limits CD4+ T cell clonal expansion in response to primary Ag stimulation. A, A total of 2 x 106 CFSE-labeled Rag2–/– 5C.C7 CD4+ T cells, either Cblb+/+ (filled bars) or Cblb–/– (open bars), were adoptively transferred into normal B10.A recipient mice and treated either with PBS alone or 5 µg PCCp. Four days later, animals were sacrificed and the LN cells were mixed with counting beads and then analyzed by flow cytometry. Numbers of CFSE+ CD4+ T cells recovered from the LN are shown. B, Adoptive transfer recipient animals were immunized either with PBS alone (black tracing) or with 1 µg PCCp (gray tracing), and 3 days later CFSE dye dilution by wild-type (left panel) or Cblb–/– (right panel) spleen 5C.C7 CD4+ T cells was measured. C, Average cell division response for either wild-type (filled bars) or Cblb–/– (open bars) LN 5C.C7 CD4+ T cells determined 4 days after immunization with PCCp as indicated. Error bars indicate the SEM for at least six animals per group. LN and spleen T cells gave similar results in these experiments.

To better understand the mechanism by which Cbl-b antagonizes Ag-dependent cell cycle progression in vivo, we examined the dose-response curve for Ag recognition by wild-type and Cblb^–/– 5C.C7 CD4⁺ T cells. A titration of Ag in the immunization regimen revealed that, at higher doses of PCCp, cell divisions were inhibited in wild-type cells as compared with the Cbl-b-deficient CD4⁺ T cells (Fig. 1C). However, at limiting Ag concentration, Cbl-b played virtually no role in the regulation of the cell division rate. Furthermore, Cblb^–/– CD4⁺ T cells demonstrated no increased sensitivity to Ag, using CD69 and CD25 as markers of productive TCR engagement (Fig. 2). Consequently, our data offered no support for a model in which basal Cbl-b expression in naive CD4⁺ T cells raises the threshold for initial Ag recognition. Rather, the data were more compatible with the hypothesis that Cbl-b expression or activity is increased only in response to intensified or prolonged TCR stimulation.

View larger version (22K): [in this window] [in a new window]   FIGURE 2. Cbl-b does not raise the threshold for initial Ag recognition. A total of 2 x 106 CFSE-labeled Rag2–/– 5C.C7 CD4+ T cells were adoptively transferred into B10.A recipients and exposed to varying doses of PCCp. Then, 5 h later, animals were sacrificed and CFSE-labeled LN CD4+ T cells were examined for expression of activation markers. A, CD25 expression by T cells from wild-type (top) and Cbl-b-deficient (bottom) donor mice exposed to either 0 (shaded histogram), 0.5 (solid tracing), 2.0 (dashed tracing), or 5 µg (dotted tracing) PCCp infusion. B, CD69 expression by wild-type (open square) and Cbl-b-deficient (closed circle) CD4+ T cells following immunization with the indicated dose of PCCp. Two to three animals were examined at each dose of Ag, and data are expressed as the mean fluorescence intensity ± SEM.

Previously, we observed that toward the end of a primary CD4⁺ T cell response to Ag stimulation in vivo, the rate of cell division and mean cell size were highly correlated (7). Based on this, we have postulated that a T cell’s ability to achieve a blastogenesis after each successive round of cell division determines the subsequent cell division time. Given that in our experiments Cbl-b appeared to play no role in the regulation of the threshold for initial Ag recognition, we hypothesized that Cbl-b does not increase the time to first cell division, but rather slows subsequent cell divisions by inhibiting the rate of G₁S phase transition. A careful time course of in vivo CD4⁺ T cell activation demonstrated that wild-type 5C.C7 CD4⁺ T cells initiated and completed the majority of their cell divisions between 24 and 48 h (Fig. 3). Cbl-b-deficient T cells also initiated their proliferative response between 24 and 48 h, and demonstrated only a modestly increased cell division rate during this period as compared with the wild-type controls. Nevertheless, between 48 and 72 h of stimulation, the Cbl-b knockout T cells divided at least once more, suggesting that Cbl-b activity was most important to suppress cell divisions at the end of a response.

View larger version (32K): [in this window] [in a new window]   FIGURE 3. Reduced CD71 expression in Cblb-expressing CD4+ T cells predicts a premature cessation of cell cycle progression. A, Wild-type (gray tracing) and Cblb–/– (open tracing) LN 5C.C7 CD4+ T cells were examined for CFSE dye dilution, CD71 expression, and cell size at various times after immunization with 5 µg PCCp. B, Spleen 5C.C7 CD4+ T cell CD71 levels expressed as a function of CFSE content. Plots are representative of four individual animals. The LN and spleen results were found to be similar.

The induction of Cbl-b both inhibits programming for autonomous cell division in the absence of ongoing TCR stimulation and desensitizes CD4⁺ T cells to low numbers of Ag/MHC complexes

Several reports have now demonstrated that CD4⁺ T cells remain fully aware of the continued presence of peptide Ag/MHC complexes throughout their primary clonal expansion. Intense competition for limiting Ag/MHC complexes at late times after initial Ag encounter leads to dissolution of CD4⁺ T cell/dendritic cell conjugates and, eventually, exit of T cells from the cell cycle (4, 5, 6, 7). Given that Cbl-b does not appear to raise the threshold for initial Ag/MHC recognition in vivo, but instead promotes the cessation of cell division, we hypothesized that Cbl-b molecules are induced during the course of a primary Ag encounter to play a counter-regulatory role.

Consistent with this model, the activation of wild-type 5C.C7 CD4⁺ T cells in vitro led to a large increase in Cbl-b protein expression by 8 h of incubation that was sustained beyond 72 h (Fig. 4A). Ligation of the TCR/CD3 complex with CD3 mAb alone proved sufficient to induce this initial rise in Cbl-b protein levels. It was previously suggested that CD28 signaling increases the rate of Cbl-b turnover in T cells and reduces protein expression (26). We, too, found some evidence for this CD28-Cbl-b antagonism at the 4-h time point; nevertheless, T cells stimulated with a combination of CD3 and CD28 mAbs ultimately demonstrated an increased Cbl-b protein level at the latest time points, perhaps as a consequence of sustained blastogenesis and improved in vitro T cell viability in the presence of CD28 costimulatory signaling (Fig. 4A and data not shown). Based on these data, it appeared that Cbl-b would have the greatest opportunity to exert its counter-regulatory effects at late times during T cell activation.

View larger version (38K): [in this window] [in a new window]   FIGURE 4. Cbl-b up-regulation is associated with decreased proliferative potential. A, Cbl-b and actin protein levels were compared in normal 5C.C7 CD4+ T cells over time following stimulation in vitro with 1 µg/ml immobilized CD3 and/or 1 µg/ml soluble CD28 mAb as indicated. B, CFSE-labeled wild-type (gray tracing) and Cblb–/– (open tracing) 5C.C7 CD4+ T cells were stimulated in vitro for 24 h with a combination of 1 µg/ml immobilized CD3 mAb and 5 µg/ml soluble CD28 mAb (or with no mAb as a control), and then were adoptively transferred into normal B10.A mice without immunization. CFSE dye dilution 3 days later is shown for LN and spleen 5C.C7 CD4+ T cells. C, As in B, the T cells were stimulated with 1 µg/ml immobilized CD3 mAb alone and subsequently adoptively transferred either in the absence (left panel) or presence (right panel) of 1 µg PCCp, and then LN 5C.C7 CD4+ T cells were analyzed for CFSE dye dilution 4 days later. Results were reproduced in three independent experiments. Spleen T cells gave similar findings.

In addition to its effects on the programming of T cells for Ag-independent cell cycle progression, Cbl-b also reduced the sensitivity of primed CD4⁺ T cells to low doses of Ag at late times during their activation response. Following an overnight period of in vitro activation with CD3 mAb alone, the Cblb^–/– 5C.C7 CD4⁺ T cells typically divided only once after adoptive transfer into unimmunized hosts (Fig. 4B). Transfer into a recipient animal that was also immunized with a low dose (1 µg) of PCCp, however, led to another round of cell division. In contrast, wild-type 5C.C7 CD4⁺ T cells demonstrated essentially no increased proliferation after transfer into PCCp-immunized mice. Taken together, the results indicated that Cbl-b molecules induced during the first 24 h of TCR/CD3 ligation both put a brake on subsequent cell division in the absence of Ag as well as desensitizedthe CD4⁺ T cells to further TCR signaling.

Cbl-b dampens IL-2 production and CD25 expression during the first 24 h of stimulation

To investigate further this capacity of Cbl-b to regulate programming for proliferation in the absence of ongoing Ag stimulation, we examined autocrine IL-2 production and response in vitro. Consistent with previous reports (11, 12), Cbl-b-deficient Rag2^–/– 5C.C7 CD4⁺ T cells demonstrated heightened IL-2 synthesis upon stimulation with either CD3 mAb alone or with the combination of CD3 and CD28 mAbs (Fig. 5, A and B). Furthermore, the pattern of in vitro CD25 and CD71 expression was altered by the Cblb gene deletion. Therefore, it appeared that newly synthesized Cbl-b molecules could antagonize the production of IL-2 and functional IL-2 receptors in vitro as well as inhibit the expression of CD71 during the first 24 h of Ag stimulation. Accordingly, a reduction in IL-2 receptor signaling and limiting iron stores following Cbl-b induction may lead to eventual growth arrest late during a clonal expansion.

View larger version (37K): [in this window] [in a new window]   FIGURE 5. Cbl-b limits the induction of IL-2, CD25, and CD71 expression during the first 22 h of T cell activation. A, Cblb+/+ or Cblb–/– 5C.C7 CD4+ T cells were stimulated 22 h in vitro with either 2 µg/ml immobilized CD3 mAb alone or a combination of immobilized CD3 mAb plus 2 µg/ml soluble CD28 mAb, as indicated. Brefeldin A (10 µg/ml) was added 9 h into the stimulation period. At the end of the experiment, 5C.C7 CD4+ T cells were examined by flow cytometry for intracellular IL-2 accumulation using IL-2-PE (open tracing) or isotype control PE-coupled mAb (gray tracing). B, Cumulative IL-2 production data for the experiment shown in A, expressed as the product % IL-2+ x mean fluorescence intensity. Error bars indicate the SEM for four replicate samples per group. C, Stimulation of 5C.C7 CD4+ T cells (either Cblb+/+, top; or Cblb–/–, bottom) for 22 h with either medium alone (nil), or with 0.5 µg/ml immobilized CD3 mAb alone, or with immobilized CD3 mAb plus 0.5 µg/ml soluble CD28 mAb. At the end of the in vitro stimulation, viable CD4+ T cells were examined for CD25 and CD71 expression. All results shown were reproduced in at least one additional experiment.

The finding that Cbl-b is expressed and can inhibit TCR-triggered activation events within the first 24 h of stimulation complicated our initial interpretation of blocked late cell cycle progression. TCR antagonism by Cbl-b molecules during the first 24 h of activation may have simply blunted the blastogenesis response and ensured a premature exit from cell cycle by rapidly dividing T cells. Alternatively, up-regulated Cbl-b molecules (or their downstream target proteins) effectively antagonize the TCR throughout clonal expansion.

To differentiate these two possibilities, we took advantage of the calcium ionophore ionomycin and the PKC-activating phorbol ester PMA to initiate a strong G₀G₁ phase progression that was independent of regulation by Cbl-b. As shown in Fig. 6, the combination of ionomycin and PMA strongly induced IL-2 production by CD4⁺ T cells, independent of the status of the Cblb gene. Similarly, 16 h of ionomycin plus PMA stimulation was sufficient to up-regulate an equivalently high level of CD71 and CD25 in both the wild-type and Cbl-b-deficient CD4⁺ T cells. Cbl-b protein expression was also strongly induced by 16 h of ionomycin and PMA stimulation (data not shown); therefore, the downstream signaling pathways triggered by these two agents and necessary for IL-2, CD71, and CD25 protein induction appeared to be insensitive to counter-regulation by Cbl-b. This failure of Cbl-b to act as an inhibitor in the absence of TCR/CD3 signals was revealing and further supported the model that Cbl-b targets TCR proximal signaling pathways for counter-regulation.

View larger version (23K): [in this window] [in a new window]   FIGURE 6. Cbl-b counter-regulation of TCR/CD3 signaling is bypassed by ionomycin and PMA. Wild-type and Cbl-b-deficient 5C.C7 CD4+ T cells were stimulated 16 h in vitro either with medium alone (nil), 1 µg/ml immobilized CD3 mAb plus 2 µg/ml soluble CD28 mAb (CD3/CD28), or with the combination of 0.5 µM ionomycin and 10 ng/ml PMA (Iono/PMA). A, IL-2 secretion into the supernatant with error bars indicating the SEM of triplicate samples. B, CD71 and CD25 expression of wild-type (gray tracing) and Cbl-b-deficient (open tracing) CD4+ T cells, determined in parallel by flow cytometry. The experiments were repeated twice more with similar results.

View larger version (46K): [in this window] [in a new window]   FIGURE 7. Cbl-b inhibits TCR/CD3 downstream signaling at late times after initial CD4+ T cell activation. Wild-type (WT) and Cblb gene knockout (KO) 5C.C7 CD4+ T cells were activated in vitro for 16 h in the presence of 0.4 µM ionomycin plus 10 ng/ml PMA. One aliquot of preactivated T cells was washed free of pharmacological agents and rested in culture for an additional 2 h, after which the T cells were then exposed to 1 µg/ml immobilized CD3 mAb for the times indicated (A) or incubated with human rIL-2 for 30 m at the concentrations shown (B). Cbl-b and actin, as well as phospho-PLC, -Akt, -ERK, and -STAT5 levels were determined by Western blotting. Note that the phospho-Akt and -ERK bands shown in B have been linearly amplified for clarity. Average band densities for individual samples (without amplification) are shown beneath each band. In a second aliquot of preactivated Cblb+/+ (gray tracing) and Cblb–/– (open tracing) 5C.C7 CD4+ T cells, CFSE dye dilution was measured either 4 days after adoptive transfer into mice immunized with either PBS alone (left panel) or 5 µg PCCp (right panel) (C), or 3 days after washing and in vitro cultivation in the presence of hrIL-2 (D).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

Cbl-b has previously been implicated in the inhibition of p85 PI3K downstream signaling to NFB (11, 13, 14, 15). We, therefore, chose to investigate this molecule in these studies based on our own in vitro data indicating a requirement for TCR- and CD28-dependent PI3K signaling to maintain an optimal rate of cell division at late time points after the initial Ag encounter (22). This study now establishes that, during a primary response to Ag stimulation in the absence of adjuvant or infection, the rate of cell division by CD4⁺ T cells that have already committed to a proliferative response becomes limited by their induction of Cbl-b protein and its subsequent inhibition of TCR-dependent proximal signaling events. Cbl-b molecules (and/or their target proteins) not only desensitize CD4⁺ T cell blasts to low numbers of Ag/MHC complexes at late times after the initiation of priming but also promote early exit from the cell cycle in the absence of ongoing TCR signaling.

These experiments were designed to address the concern that changes in T cell signaling observed in the absence of Cblb are a consequence, rather than cause, of the spontaneous autoimmune disease that has sometimes been observed in these mice (11, 12). Use of the 5C.C7 TCR-Tg on the Rag2^–/– background precluded the development of an autoreactive CD4⁺ T cell repertoire in the Cblb^–/– animals and prevented disease in our experiments. Adoptive transfer of these CD4⁺ T cells into normal hosts also eliminated the effect of a loss of Cbl-b expression in other immune cells or tissues. Therefore, one can be confident that these results have not been confounded by some alteration in the specificity or differentiation state of the responder CD4⁺ T cell population or by a secondary effect of systemic inflammation or non-T cell Cbl-b deficiency.

It is most important to note that this investigation did not reveal in vivo evidence for control of naive CD4⁺ T cell initial recognition of Ag by Cbl-b. This result is remarkable given previous studies that have reported a selective capacity of Cbl-b molecules in naive T cells to interrupt signaling between p85 PI3K and NFB even within the first 30 min of in vitro activation (11, 12, 13, 14, 15). We, too, have observed a capacity of Cbl-b to selectively antagonize NFB translocation to the nucleus 4 h into an in vitro activation, particularly when CD28 costimulatory signals are lacking (R. Zhang, unpublished observation). Nevertheless, such alterations in PI3K and NFB activation may be relatively unimportant to establishing the threshold for T cell activation in vivo, at least as measured by the early induction of CD69 and CD25 expression. Alternatively, early B7/CD28 interactions (even in the absence of infection) may be sufficient to overcome any inhibitory effect of a few Cbl-b molecules and allow for adequate early PI3K and NFB signaling in vivo. Consistent with this latter theory, previously published in vitro activation studies have suggested that the costimulation of T cell cultures with anti-CD28 mAb alleviates much of the counter-regulatory effect of Cbl-b (26). The induction of CD69 and CD25 is thought to depend at least in part on the activation of NFB (28, 29). Therefore, it is more likely that early during Ag priming of CD4⁺ T cells in vivo there is insufficient Cbl-b activity to overcome the effects of CD28 costimulatory signaling and inhibit TCR signaling to PI3K, Akt, and NFB.

In contrast to its inability to effectively antagonize initial Ag/MHC recognition in vivo, or prevent an early increase in cell size and CD71 surface expression by the Ag-specific CD4⁺ T cells, Cbl-b did prove important in the exit of these T cells from cell cycle during the period between 48 and 72 h. Although the mechanism of this counter-regulation remains uncertain, Cbl-b expression was associated with a premature reduction in cell size and CD71 by 48 h. Our previous studies have implicated a CD28/PI3K/Akt/mTOR signaling pathway as necessary to maintain CD4⁺ T cells in cell cycle following Ag stimulation in vitro (22, 30). Others have shown that the expression CD71 relies on signals mediated by PI3K and mTOR (25), and our own unpublished experiments confirm this (R. Zhang, unpublished observations). Therefore, we now speculate that during the in vivo primary response to Ag, PI3K, mTOR, and NFB activities wane as Cbl-b protein levels rise and desensitize the CD4⁺ T cells to further Ag stimulation, thus quenching their remaining proliferative program. It also follows that during a primary response to Ag in the presence of an adjuvant or infection, or in the clinical setting of systemic inflammation, increased PI3K activity associated with enhanced CD28 and OX40 costimulatory receptor signaling overcomes the negative effects of Cbl-b and facilitates a more durable clonal expansion response via the induction of mTOR regulators such as survivin and aurora B (31, 32).

Results obtained by others using P14 TCR-transgenic CD8⁺ T cells primed during lymphocytic choriomeningitis virus infection support the conclusions that Cbl-b cannot interrupt early Ag recognition or entry into cell cycle by naive T cells, but instead puts a brake on late TCR signaling (33). Because CD8⁺ T cells can be programmed for a durable clonal expansion, without need for persistent Ag recognition to maintain a high rate of cell division, the up-regulation of Cbl-b and subsequent TCR down-modulation are not accompanied by a slowing of the rate of proliferation (33, 34). In contrast, Cblb^–/– P14 CD8⁺ T cells do demonstrate augmented IFN- production on Ag rechallenge, consistent with a need for continuous TCR signaling to ensure optimal effector T cell generation and a capacity for Cbl-b to interfere with this TCR-dependent differentiation event (33, 35).

It is interesting that Cbl-b counter-regulates TCR/CD3-dependent activation signals but does not inhibit IL-2 receptor signaling in blasting CD4⁺ T cells. Like the TCR, IL-2 receptors are thought to activate PI3K, with PI3K activity necessary for expression of cyclin D3 and degradation of p27kip1 before entry into cell cycle (36). Therefore, it might have been reasonable to expect that Cbl-b would also antagonize late IL-2-dependent PI3K signaling and cell cycle progression by 5C.C7 CD4⁺ T cell blasts. However, experiments shown here using ionomycin plus PMA-generated CD4⁺ T cell blasts (or T cells pretreated with CD3 and CD28 mAb; data not shown) did not demonstrate a significant increase in Akt phosphorylation during the first 30 m of exposure to the cytokine. In contrast, IL-2 was sufficient to stimulate equally the phosphorylation of STAT5 in both Cbl-b-expressing and Cbl-b-deficient CD4⁺ T cell blasts. IL-2 treatment was also observed to protect both Cblb^–/– and wild-type CD4⁺ T cell blasts from growth factor withdrawal-induced cell death (R. Zhang, unpublished observation). Perhaps consistent with a dominant role for phospho-STAT5-dependent and Cbl-b/PI3K-independent signaling pathways in IL-2-triggered cell growth and survival in vitro, the PI3K inhibitor LY294002 blocks neither the expression of cyclin D3 and cyclin E nor the down-regulation of p27kip1 at late time points after treatment with IL-2 (37). Taken together, the data suggest there is little opportunity for Cbl-b to antagonize IL-2-dependent late cell signaling events. This capacity of IL-2 receptors to bypass the counter-regulatory effects of Cbl-b may help explain how IL-2 can promote a reversal of clonal anergy in CD4⁺ T cells despite their high expression of Cbl-b (16, 17, 18, 38). Thus, the ability of Cbl-b to counter-regulate late cell cycle progression in our adoptive transfer system is most consistent with the model that IL-2 is neither necessary nor sufficient to mediate CD4⁺ T cell proliferation in vivo (39).

In summary, this work details a new role for Cbl-b in the late regulation of CD4⁺ T cell clonal expansion following a primary recognition of Ag. The accumulation of Cbl-b protein hours to days into an immune response antagonizes TCR-dependent proximal signal transduction and imposes a requirement for continued strong TCR signaling to maintain a high rate of cell division. When Ag/MHC complexes can no longer be detected during the course of a clonal expansion as a consequence of this Cbl-b-dependent desensitization, CD4⁺ T cells then fail to maintain their expression of transferrin receptors (CD71) and undergo a premature growth arrest that prevents additional G₁S phase transitions. Such counter-regulation of TCR-dependent late cell growth by Cbl-b may underlie its ability to act as a barrier to the development of autoimmune disease following self Ag recognition.

	Acknowledgments

 
We thank M. Jenkins and S. Jameson for reading of the manuscript and thoughtful comments.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by grants from the North Central Chapter Arthritis Foundation and National Institutes of Health Grants P01 AI35296 and R01 GM54706.

² Address correspondence and reprint requests to Dr. Daniel L. Mueller, Department of Medicine and Center for Immunology, University of Minnesota Medical School, MMC 334, 6-120 Nils Hasselmo Hall, 312 Church Street, Southeast, Minneapolis, MN 55455. E-mail address: muell002{at}umn.edu

³ Abbreviations used in this paper: Cbl-b, Casitas B-lineage lymphoma b; mTOR, mammalian target of rapamycin; PCCp, pigeon cytochrome c peptide 81-104; PKC, protein kinase C; Tg, transgenic; LN, lymph node.

Received for publication March 27, 2008. Accepted for publication August 7, 2008.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184: 747-752. [Abstract/Free Full Text]
2. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388: 782-787. [Medline]
3. Iezzi, G., K. Karjalainen, A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8: 89-95. [Medline]
4. Obst, R., H. M. van Santen, D. Mathis, C. Benoist. 2005. Antigen persistence is required throughout the expansion phase of a CD4⁺ T cell response. J. Exp. Med. 201: 1555-1565. [Abstract/Free Full Text]
5. Obst, R., H. M. van Santen, R. Melamed, A. O. Kamphorst, C. Benoist, D. Mathis. 2007. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc. Natl. Acad. Sci. USA 104: 15460-15465. [Abstract/Free Full Text]
6. Celli, S., F. Lemaitre, P. Bousso. 2007. Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4⁺ T cell activation. Immunity 27: 625-634. [Medline]
7. Yarke, C. A., S. L. Dalheimer, N. Zhang, D. M. Catron, M. K. Jenkins, D. L. Mueller. 2008. Proliferating CD4⁺ T cells undergo immediate growth arrest upon cessation of TCR signaling in vivo. J. Immunol. 180: 156-162. [Abstract/Free Full Text]
8. Smith, A. L., M. E. Wikstrom, B. Fazekas de St. Groth. 2000. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 13: 783-794. [Medline]
9. Hataye, J., J. J. Moon, A. Khoruts, C. Reilly, M. K. Jenkins. 2006. Naive and memory CD4⁺ T cell survival controlled by clonal abundance. Science 312: 114-116. [Abstract/Free Full Text]
10. Yokoi, N., K. Komeda, H. Y. Wang, H. Yano, K. Kitada, Y. Saitoh, Y. Seino, K. Yasuda, T. Serikawa, S. Seino. 2002. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nat. Genet. 31: 391-394. [Medline]
11. Chiang, Y. J., H. K. Kole, K. Brown, M. Naramura, S. Fukuhara, R. J. Hu, I. K. Jang, J. S. Gutkind, E. Shevach, H. Gu. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216-220. [Medline]
12. Bachmaier, K., C. Krawczyk, I. Kozieradzki, Y. Y. Kong, T. Sasaki, A. Oliveira-dos-Santos, S. Mariathasan, D. Bouchard, A. Wakeham, A. Itie, et al 2000. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403: 211-216. [Medline]
13. Qiao, G., Z. Li, L. Molinero, M. L. Alegre, H. Ying, Z. Sun, J. M. Penninger, J. Zhang. 2008. T-cell receptor-induced NF-B activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol. Cell. Biol. 28: 2470-2480. [Abstract/Free Full Text]
14. Fang, D., Y. C. Liu. 2001. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat. Immunol. 2: 870-875. [Medline]
15. Fang, D., H. Y. Wang, N. Fang, Y. Altman, C. Elly, Y. C. Liu. 2001. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J. Biol. Chem. 276: 4872-4878. [Abstract/Free Full Text]
16. Heissmeyer, V., F. Macian, S. H. Im, R. Varma, S. Feske, K. Venuprasad, H. Gu, Y. C. Liu, M. L. Dustin, A. Rao. 2004. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat. Immunol. 5: 255-265. [Medline]
17. Jeon, M. S., A. Atfield, K. Venuprasad, C. Krawczyk, R. Sarao, C. Elly, C. Yang, S. Arya, K. Bachmaier, L. Su, et al 2004. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21: 167-177. [Medline]
18. Safford, M., S. Collins, M. A. Lutz, A. Allen, C. T. Huang, J. Kowalski, A. Blackford, M. R. Horton, C. Drake, R. H. Schwartz, J. D. Powell. 2005. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 6: 472-480. [Medline]
19. Kaye, J., S. M. Hedrick. 1988. Analysis of specificity for antigen, Mls, and allogenic MHC by transfer of T-cell receptor - and β-chain genes. Nature 336: 580-583. [Medline]
20. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84: 1374-1378. [Abstract/Free Full Text]
21. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, J. P. Allison. 1992. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609. [Medline]
22. Bonnevier, J. L., C. A. Yarke, D. L. Mueller. 2006. Sustained B7/CD28 interactions and resultant phosphatidylinositol 3-kinase activity maintain G(1)->S phase transitions at an optimal rate. Eur. J. Immunol. 36: 1583-1597. [Medline]
23. Vanasek, T. L., A. Khoruts, T. Zell, D. L. Mueller. 2001. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 167: 5636-5644. [Abstract/Free Full Text]
24. Lyons, A. B., C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137. [Medline]
25. Zheng, Y., S. L. Collins, M. A. Lutz, A. N. Allen, T. P. Kole, P. E. Zarek, J. D. Powell. 2007. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 178: 2163-2170. [Abstract/Free Full Text]
26. Zhang, J., T. Bardos, D. Li, I. Gal, C. Vermes, J. Xu, K. Mikecz, A. Finnegan, S. Lipkowitz, T. T. Glant. 2002. Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination. J. Immunol. 169: 2236-2240. [Abstract/Free Full Text]
27. Garcia, Z., E. Pradelli, S. Celli, H. Beuneu, A. Simon, P. Bousso. 2007. Competition for antigen determines the stability of T cell-dendritic cell interactions during clonal expansion. Proc. Natl. Acad. Sci. USA 104: 4553-4558. [Abstract/Free Full Text]
28. Ruben, S., H. Poteat, T. H. Tan, K. Kawakami, R. Roeder, W. Haseltine, C. A. Rosen. 1988. Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. Science 241: 89-92. [Abstract/Free Full Text]
29. Lopez-Cabrera, M., E. Munoz, M. V. Blazquez, M. A. Ursa, A. G. Santis, F. Sanchez-Madrid. 1995. Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor--responsive elements. J. Biol. Chem. 270: 21545-21551. [Abstract/Free Full Text]
30. Bonnevier, J. L., D. L. Mueller. 2002. Cutting edge: B7/CD28 interactions regulate cell cycle progression independent of the strength of TCR signaling. J. Immunol. 169: 6659-6663. [Abstract/Free Full Text]
31. Song, J., S. Salek-Ardakani, T. So, M. Croft. 2007. The kinases aurora B and mTOR regulate the G₁-S cell cycle progression of T lymphocytes. Nat. Immunol. 8: 64-73. [Medline]
32. Song, J., T. So, M. Cheng, X. Tang, M. Croft. 2005. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22: 621-631. [Medline]
33. Shamim, M., S. G. Nanjappa, A. Singh, E. H. Plisch, S. E. LeBlanc, J. Walent, J. Svaren, C. Seroogy, M. Suresh. 2007. Cbl-b regulates antigen-induced TCR down-regulation and IFN- production by effector CD8 T cells without affecting functional avidity. J. Immunol. 179: 7233-7243. [Abstract/Free Full Text]
34. Mercado, R., S. Vijh, S. E. Allen, K. Kerksiek, I. M. Pilip, E. G. Pamer. 2000. Early programming of T cell populations responding to bacterial infection. J. Immunol. 165: 6833-6839. [Abstract/Free Full Text]
35. Van Stipdonk, M. J., G. Hardenberg, M. S. Bijker, E. E. Lemmens, N. M. Droin, D. R. Green, S. P. Schoenberger. 2003. Dynamic programming of CD8⁺ T lymphocyte responses. Nat. Immunol. 4: 361-365. [Medline]
36. Brennan, P., J. W. Babbage, B. M. Burgering, B. Groner, K. Reif, D. A. Cantrell. 1997. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7: 679-689. [Medline]
37. Colombetti, S., V. Basso, D. L. Mueller, A. Mondino. 2006. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 176: 2730-2738. [Abstract/Free Full Text]
38. Colombetti, S., F. Benigni, V. Basso, A. Mondino. 2002. Clonal anergy is maintained independently of T cell proliferation. J. Immunol. 169: 6178-6186. [Abstract/Free Full Text]
39. Khoruts, A., A. Mondino, K. A. Pape, S. L. Reiner, M. K. Jenkins. 1998. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187: 225-236. [Abstract/Free Full Text]

This article has been cited by other articles:

				M.-C. St. Rose, H. Z. Qui, S. Bandyopadhyay, M. A. Mihalyo, A. T. Hagymasi, R. B. Clark, and A. J. Adler The E3 Ubiquitin Ligase Cbl-b Regulates Expansion but Not Functional Activity of Self-Reactive CD4 T Cells J. Immunol., October 15, 2009; 183(8): 4975 - 4983. [Abstract] [Full Text] [PDF]

				J. T. Lin, N. B. Lineberry, M. G. Kattah, L. L. Su, P. J. Utz, C. G. Fathman, and L. Wu Naive CD4 T Cell Proliferation Is Controlled by Mammalian Target of Rapamycin Regulation of GRAIL Expression J. Immunol., May 15, 2009; 182(10): 5919 - 5928. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, R. Articles by Mueller, D. L. Search for Related Content PubMed PubMed Citation Articles by Zhang, R. Articles by Mueller, D. L.